A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

• Status: Recruiting
• Trial end date: 2023-06-04
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to describe the safety, tolerability, and immunogenicity of MenABCWY in healthy infants 2 and 6 months of age.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Acetaminophen

Criteria

Inclusion Criteria:

1. Male and female participants, 2 months of age (≥60 to ≤98 days) or 6 months of age (≥150 to ≤210 days) at the time of randomization.

2. Participant's parent(s)/legal guardian who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

3. Participant is available for the entire study period and the participant's parent(s)/legal guardian can be reached by telephone.

4. Healthy participant as determined by medical history, physical examination, and judgment of the investigator.

5. Body weight ≥4 kg for participants 2 months of age at the time of randomization.

6. Participants whose parent(s)/legal guardian are capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion Criteria:

1. Prior adverse reaction to paracetamol use, including allergic reactions.

2. Participant was born prematurely (<37 weeks of gestation).

3. A previous anaphylactic reaction to any vaccine or vaccine-related component.

4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.

5. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as participants with congenital or acquired defects in B-cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Please refer to the SRM for additional details.

6. History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.

7. Significant neurological disorder or history of seizure (including simple febrile seizure).

8. Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

9. Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

10. Previous vaccination with any meningococcal vaccine. Written vaccination history must be obtained prior to randomization.

11. For participants 2 months of age, prior vaccination with any of the following licensed or investigational vaccines: pneumococcal vaccine and hexavalent DTPa-HBV-IPV-Hib or its component, except for the birth dose of hepatitis B vaccine.

12. Participants receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.

13. Receipt of any blood products, including immunoglobulin, before the first study vaccination.

14. Current chronic use of systemic antibiotics.

15. Participation in other studies involving investigational drug(s) or investigational vaccine(s) within 28 days prior to study entry and/or during study participation.